Skip to main content
Article thumbnail
Location of Repository

Study design and methods of the BoTULS trial: a randomised controlled trial to evaluate the clinical effect and cost effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A

By Helen Rodgers, Lisa Shaw, Christopher Price, Frederike van Wijck, Michael Barnes, Laura Graham, Gary Ford, Phil Shackley, Nick Steen and On behalf of BoTULS investigators


Background\ud Following a stroke, 55–75% of patients experience upper limb problems in the longer term. Upper limb spasticity may cause pain, deformity and reduced function, affecting mood and independence. Botulinum toxin is used increasingly to treat focal spasticity, but its impact on upper limb function after stroke is unclear.\ud \ud The aim of this study is to evaluate the clinical and cost effectiveness of botulinum toxin type A plus an upper limb therapy programme in the treatment of post stroke upper limb spasticity.\ud \ud Methods\ud Trial design : A multi-centre open label parallel group randomised controlled trial and economic evaluation.\ud \ud Participants : Adults with upper limb spasticity at the shoulder, elbow, wrist or hand and reduced upper limb function due to stroke more than 1 month previously.\ud \ud Interventions : Botulinum toxin type A plus upper limb therapy (intervention group) or upper limb therapy alone (control group).\ud \ud Outcomes : Outcome assessments are undertaken at 1, 3 and 12 months. The primary outcome is upper limb function one month after study entry measured by the Action Research Arm Test (ARAT). Secondary outcomes include: spasticity (Modified Ashworth Scale); grip strength; dexterity (Nine Hole Peg Test); disability (Barthel Activities of Daily Living Index); quality of life (Stroke Impact Scale, Euroqol EQ-5D) and attainment of patient-selected goals (Canadian Occupational Performance Measure). Health and social services resource use, adverse events, use of other antispasticity treatments and patient views on the treatment will be compared. Participants are clinically reassessed at 3, 6 and 9 months to determine the need for repeat botulinum toxin type A and/or therapy.\ud \ud Randomisation : A web based central independent randomisation service.\ud \ud Blinding : Outcome assessments are undertaken by an assessor who is blinded to the randomisation group.\ud \ud Sample size : 332 participants provide 80% power to detect a 15% difference in treatment successes between intervention and control groups. Treatment success is defined as improvement of 3 points for those with a baseline ARAT of 0–3 and 6 points for those with ARAT of 4–56

Publisher: BioMed Central
Year: 2008
OAI identifier:

Suggested articles


  1. (1983). VA: Recovery after stroke. doi
  2. (1987). E: Arm function after stroke: measurement and recovery over the first three months. doi
  3. (2005). GR: Spasticity: clinical perceptions, neurological realities and meaningful measurement. Disability & Rehabilitation doi
  4. (1980). Symposium Synopsis. In Spasticity: Disordered Motor Control Edited by: Feldman RG,
  5. (2002). Royal College of Physicians: Guidelines for the use of botulinum toxin (BTX) in the management of spasticity in adults.
  6. (2001). A: The management of adults with spasticity using botulinum toxin: a guide to clinical practice. Radius Healthcare,
  7. (1996). EP: Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology doi
  8. (1998). Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo-controlled trial. Clinical Rehabilitation doi
  9. (2000). C: A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke doi
  10. (2000). JM: Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo-controlled trial. doi
  11. (2001). L: A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. doi
  12. (2002). Turkel C: Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after stroke. doi
  13. (2004). Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebocontrolled trial. doi
  14. (2004). PT: Dose-dependent response to intramuscular botulinum toxin type A for upperlimb spasticity in patients after a stroke. Archives of Physical Medicine & Rehabilitation doi
  15. (2005). Suwanwela NC: The lowest effective dose of botulinum A toxin in adult patients with upper limb spasticity. Disability & Rehabilitation doi
  16. (2002). Treatment of upper extremity spasticity in stroke patients by focal neuroTrials 2008, 9:59 nal or neuromuscular blockade: a systematic review of the literature. doi
  17. (2005). A: Botulinum toxin type A for the treatment of the upper limb spasticity after stroke: a meta-analysis. Arquivos de Neuro-Psiquiatria doi
  18. (2005). Botulinum Toxin A for upper and lower limb spasticity: a systematic review [Technology report no 51] Ottawa: Canadian Coordinating Office for Health Technology Assessment;
  19. (2007). Trialists Collaboration: Organised inpatient (stroke unit) care for stroke. Cochrane Database Syst Rev doi
  20. (1981). A performance test for assessment of upper limb function in physical rehabilitation treatment and research. doi
  21. (1980). Robaye E: Motor evaluation in vascular hemiplegia. European Neurology doi
  22. (1989). Hewer RL: Arm function after stroke. An evaluation of grip strength as a measure of recovery and a prognostic indicator. doi
  23. (1982). The nine hole peg test of finger hand coordination for the hemiplegic patient. In Mossman's A Problem Orientated Approach to Stroke Rehabilitation Second edition. Illinois: Charles C Thomas;
  24. (1987). MB: Interrater reliability of a modified Ashworth scale of muscle spasticity. Physical Therapy
  25. (1990). The Canadian Occupational Performance Measure: An Outcome Measure for Occupational Therapy. doi
  26. (1965). DW: Functional Evaluation: the Barthel Index.
  27. (2003). Rasch analysis of a new stroke-specific outcome scale: the Stroke Impact Scale. doi
  28. (1990). Euroquol – a new facility for the measurement of health-related quality of life. Health Policy
  29. (1994). SW: A comparison of pain measurement characteristics of mechanical visual analogue and simple numerical rating scales. Pain doi
  30. (1972). Evaluation of a mental test score for assessment of mental impairment in the elderly. Age and Ageing doi
  31. (1996). CF: Bedside screening for aphasia: a comparison of two methods. doi
  32. (1989). Interobserver agreement for the assessment of handicap in stroke patients. Stroke doi
  33. (1991). C: Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet doi
  34. (2004). Royal College of Physicians: National clinical guidelines for stroke (second edition).
  35. (1999). Goal planning in stroke rehabilitation: evidence. Topics in Stroke Rehabilitation doi
  36. (2002). Restoring movement and functional ability after stroke: now and the future. Physiotherapy doi
  37. (2001). Bouter LM: Exercise therapy for arm function in stroke patients: a systematic review of randomized controlled trials. Clinical Rehabilitation doi
  38. (1999). Intensity of leg and arm training after primary middle-cerebral-artery stroke: a randomised trial. Lancet doi
  39. (2000). Task-related circuit training improves performance of locomotor tasks in chronic stroke: a randomized, controlled pilot trial. doi
  40. RB: Task-related training improves per-
  41. (2003). RB: Stroke Rehabilitation. Guidelines for exercise training to optimise motor skill London: doi
  42. (2001). GR: Upper Motor Neurone Syndrome and Spasticity First edition. Cambridge: doi
  43. (2005). Recovery after stroke Cambridge: doi
  44. (2002). Neurological Physiotherapy 2nd edition.
  45. (2003). RD: Is hand splinting effective for adults following stroke? A systematic review and methodologic critique of published research. Clinical Rehabilitation doi
  46. (2005). Physical Management in Neurological Rehabilitation 2nd edition.
  47. (2004). The impact of physical therapy on functional outcomes after stroke: what's the evidence? Clinical Rehabilitation doi
  48. (1996). Motor learning following unilateral stroke. doi
  49. (2001). Motor Learning: Concepts and Applications
  50. (1979). RL: Contextual interference effects on the acquisition, retention and transfer of a motor skill. doi
  51. (1997). Synthesis of intervention trials to improve motor recovery following stroke. Topics in Stroke Rehabilitation
  52. (2004). Improving arm function in patients with chronic spasticity: combining botulinum toxin with a task orientated motor learning programme.
  53. (2004). Medicines for Human Use (Clinical Trials) Regulations
  54. (1997). Economics evaluation 3rd edition. doi
  55. (1997). GW: Methods for the economic evaluation of health care 2nd edition.
  56. (1996). Cost effectiveness in health and medicine doi
  57. (1998). Cost analysis of early supported hospital discharge for stroke. Age and Ageing doi
  58. (2005). DH: Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet doi
  59. Statistical Methods for Rates and Proportions doi
  60. (2002). MP: Are we underestimating the clinical efficacy of botulinum toxin (type A)? Quantifying changes in spasticity, strength and upper limb function after injections of Botox to the elbow flexors in a unilateral stroke population. Clinical Rehabilitation doi
  61. (2002). Treatment of upper extremity spasticity in stroke patients by focal neuro-Trials 2008, 9:59
  62. (1997). RB: Task-related training improves performance of seated reaching tasks after stroke. A randomized controlled trial. Stroke doi
  63. Tripartite Guideline for Good Clinical Practice []
  64. (2005). Health: Research Governance Framework for Health and Social Care. Second edition.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.